Torben Bjerregaard Larsen

Learn More
PURPOSE To evaluate effectiveness and safety of rivaroxaban versus warfarin or dabigatran etexilate in a prospective cohort of routine care non-valvular atrial fibrillation (AF) patients during February 2012 to August 2014. METHODS We identified in nationwide health registries a cohort of AF patients who were new-users of rivaroxaban 15 mg (R15) or 20 mg(More)
The present study describes 403 patients with thrombosis, from a uniform ethnic and geographical background. Two-hundred-and-seven individuals had suffered mild or moderate stroke and 196 individuals suffered venous thromboembolism. We recorded levels of antithrombin, protein C and protein S, plasminogen and plasma homocysteine, and the presence of the(More)
EHRA Scientific Committee Task Force: Bulent Gorenek (chair)1*, Antonio Pelliccia (co-chair)2, Emelia J. Benjamin3, Giuseppe Boriani4, Harry J. Crijns5, Richard I. Fogel6, Isabelle C. Van Gelder7, Martin Halle8, Gulmira Kudaiberdieva9, Deirdre A. Lane10, Torben Bjerregaard Larsen11, Gregory Y. H. Lip10, Maja-Lisa Løchen12,13, Francisco Marı́n14, Josef(More)
The age of patients presenting with complex arrhythmias is increasing. Frailty is a multifaceted syndrome characterized by an increased vulnerability to stressors and a decreased ability to maintain homeostasis. The prevalence of frailty is associated with age. The aims of this European Heart Rhythm Association (EHRA) EP Wire survey were to evaluate the(More)
Please note: Dr. Klungel has received unrestricted funding for pharmacoepidemiological research from the Dutch private-public TI pharma Mondriaan project. Dr. Singer has served as a consultant to Boehringer Ingelheim, BristolMyers Squibb, CVS Health, Johnson & Johnson, Medtronic, and Merck; and has received research support from Boehringer Ingelheim,(More)
  • 1